https://www.theguardian.com/science/2024/dec/26/scientists-explore-longevity-drugs-for-dogs-that-could-also-extend-human-life [p] Skip to main contentSkip to navigation Close dialogue1/1Next imagePrevious imageToggle caption Skip to navigation Print subscriptions Newsletters Sign in US[ ] * US edition * UK edition * Australia edition * Europe edition * International edition The Guardian - Back to homeThe Guardian [ ] * News * Opinion * Sport * Culture * Lifestyle Show moreHide expanded menu * [ ]News + View all News + US news + US politics + World news + Climate crisis + Middle East + Ukraine + Soccer + Business + Environment + Tech + Science + Newsletters + Wellness * [ ]Opinion + View all Opinion + The Guardian view + Columnists + Letters + Opinion videos + Cartoons * [ ]Sport + View all Sport + Soccer + NFL + Tennis + MLB + MLS + NBA + WNBA + NHL + F1 + Golf * [ ]Culture + View all Culture + Film + Books + Music + Art & design + TV & radio + Stage + Classical + Games * [ ]Lifestyle + View all Lifestyle + Wellness + Fashion + Food + Recipes + Love & sex + Home & garden + Health & fitness + Family + Travel + Money * Search input [ ] google-search Search + Support us + Print subscriptions + Newsletters + Download the app * + Search jobs + Digital Archive + Guardian Licensing + About Us + The Guardian app + Video + Podcasts + Pictures + Inside the Guardian + Guardian Weekly + Crosswords + Wordiply + Corrections * Search input [ ] google-search Search + Search jobs + Digital Archive + Guardian Licensing + About Us * US * US politics * World * Climate crisis * Middle East * Ukraine * Soccer * Business * Environment * Tech * Science * Newsletters * Wellness A dog walker strides along a pavement with a Jack Russell dog on leash [ ] One firm has raised $125m in funding from companies who have held back from investing in human longevity projects because of the decades those trials would take. Photograph: alexei_tm/Getty Images/ iStockphoto View image in fullscreen One firm has raised $125m in funding from companies who have held back from investing in human longevity projects because of the decades those trials would take. Photograph: alexei_tm/Getty Images/ iStockphoto Ageing Scientists explore longevity drugs for dogs that could also 'extend human life' Researchers say drugs may be able to increase lifespan by extending health and thus shortening the rate of ageing Amelia Hill Thu 26 Dec 2024 13.00 EST Share Not for nothing are dogs called man's best friend: they are good for their owners' mental and physical health, and some studies have shown that if you're looking for a date and want to seem more attractive, it might be time to get a canine companion. So what would it be like if dogs could live for ever - and what if that secret could help their owners live longer, healthier lives too? A number of companies are now finding common ground between the two goals. The Guardian view on ageing: the science of longevity is advancing | Editorial Read more Early next year, Loyal, a US biotech start-up, is confident that it will bring LOY-002, a daily, beef-flavoured pill, to market that could give dogs a minimum of one extra year of healthy life. The San Francisco-based firm has raised $125m (PS100m) in funding from companies who have held back from investing in human longevity projects because of the decades those trials would take. But Celine Halioua, founder and chief executive of Loyal - which is part of Cellular Longevity, a biotech firm researching the science of longevity - believes their work will benefit humans. "Finding out how to prevent canine age-related decline is a really strong proxy for doing the same with humans because dogs get similar age-related diseases, and share our environments and habits in ways laboratory mice do not," she said. The LOY-002 pill aims to blunt and reverse metabolic changes associated with ageing: reducing frailty by curbing ageing-related increases in insulin. "We're not making immortal dogs," said Halioua. "The way the drug extends lifespan, we hypothesise, is by extending health and thus shortening the rate of ageing." Secrets of ageing: what makes me age? - podcast Read more The same goal is being sought in another laboratory almost 900 miles across America, where a team of academic researchers are feverishly testing the impact of rapamycin as part of the Dog Aging Project. Rapamycin, a cheap, easily produced drug already commonly used as an immunosuppressant for humans after organ transplant operations, has repeatedly been shown to increase lifespan and delay - or even reverse - many age-related disorders in mice. While the drug has not been approved for longevity use in humans, many gerontologists nevertheless see it as the best hope we have for pharmacologically slowing down the ageing process. The Dog Aging Project, the first large-scale, longitudinal study of large animals in a natural environment, suggests that low doses of rapamycin could increase dogs' lifespan, improving both their heart and cognitive functions by regulating cell growth and metabolism. "Our study is light years ahead of anything that's been done on humans or can be done on humans," said Daniel Promislow, a biogerontologist at the University of Washington and a co-director of the project. "What we're doing is the equivalent of a 40-year-long study on humans, testing the ability of a drug to increase healthy lifespan." Kate Creevy, co-founder and chief veterinary officer of the project, said they were in the unique position of being able to split their findings not just by male and female dogs - but also pre- and post-spaying, or surgical sterilisation. "This means that our research could have interesting translational impacts for women pre- and post-menopause," said Creevy. "We also have data on what age dogs have been spayed - which could cross over to the variation in age that women have their menopause - and data on why they were spayed, which could cross over to women who have had hysterectomies for medical reasons." When the project finally reports in four to five years' time, Promislow hopes to be able to prove that rapamycin has the power to give dogs an extra three years of healthy life. Promislow insists that it is realistic to hope that his research could cross over to humans. "If we're successful with dogs, it could be a turning point in informing us how to give human populations extra healthy lifespan too," he said. The search to extend dogs' lives is warmly welcomed across the human longevity community. Prof Tom Rando, director of the University of California's Broad Stem Cell Research Centre and one of the most respected names in the geroscience community, said the research is "fascinating". "The work is one more piece in the puzzle that we hope will eventually give us the full picture about human longevity," he said. "The more human the animal gets that we can test our longevity drugs on, the more confidence we can have that these drugs will work on humans too," he said. "And having evidence of efficacy and safety in dogs gives us more confidence for doing human studies with these same drugs." But Jamie Justice, adjunct professor in gerontology and geriatric medicine at Wake Forest University School of Medicine, said that without a consensus among scientists on a human biomarker of ageing in the form of a simple blood test scientists cannot test any drugs on humans, no matter how positive the results are elsewhere. "Because we can't conduct 40-year-long longevity tests on humans, we need a universally agreed biomarker to show the impact of drugs on predictors of health problems that we agree correlate with ageing," she said. "The goal of science now needs to be to agree those parameters. Then the work that will yield the most exciting results of all - because they will be results we can take to market - can begin." Explore more on these topics * Ageing * Health * Dogs * Animals * Pets * news Share Reuse this content Most viewed Most viewed * US * US politics * World * Climate crisis * Middle East * Ukraine * Soccer * Business * Environment * Tech * Science * Newsletters * Wellness * News * Opinion * Sport * Culture * Lifestyle Original reporting and incisive analysis, direct from the Guardian every morning Sign up for our email * About us * Help * Complaints & corrections * SecureDrop * Work for us * * Privacy policy * Cookie policy * Terms & conditions * Contact us * All topics * All writers * Digital newspaper archive * Tax strategy * Facebook * YouTube * Instagram * LinkedIn * Newsletters * Advertise with us * Guardian Labs * Search jobs Back to top (c) 2024 Guardian News & Media Limited or its affiliated companies. All rights reserved. (dcr)